Antonelli, Flaminia
 Distribuzione geografica
Continente #
NA - Nord America 185
EU - Europa 124
AS - Asia 86
AF - Africa 6
Totale 401
Nazione #
US - Stati Uniti d'America 177
SG - Singapore 41
IT - Italia 29
CN - Cina 22
SE - Svezia 21
IE - Irlanda 17
DE - Germania 13
ID - Indonesia 13
GB - Regno Unito 12
CA - Canada 7
FI - Finlandia 7
FR - Francia 7
RU - Federazione Russa 7
IN - India 6
CI - Costa d'Avorio 5
BE - Belgio 3
NL - Olanda 3
HK - Hong Kong 2
AT - Austria 1
CH - Svizzera 1
HU - Ungheria 1
IL - Israele 1
JP - Giappone 1
LT - Lituania 1
ME - Montenegro 1
PA - Panama 1
SC - Seychelles 1
Totale 401
Città #
Chandler 45
Ashburn 29
Singapore 28
New York 24
Dublin 16
Jakarta 13
Chicago 12
Milan 12
Beijing 7
Bremen 6
London 6
Abidjan 5
Helsinki 5
Pune 5
Moscow 4
Rome 4
Toronto 4
Amsterdam 3
Bologna 3
Brussels 3
Munich 3
Ottawa 3
Paris 3
Ragusa 3
Southampton 3
Boardman 2
Boydton 2
Edinburgh 2
Frankfurt am Main 2
Hong Kong 2
Lappeenranta 2
Lyon 2
Nuremberg 2
White Salmon 2
Anchorage 1
Andover 1
Anniston 1
Besançon 1
Boston 1
Bracke 1
Budapest 1
Busto Arsizio 1
Catania 1
Dresden 1
Kochi 1
Los Angeles 1
Marseille 1
Panama City 1
Piansano 1
Podgorica 1
Princeton 1
Shijiazhuang 1
Tokyo 1
Vienna 1
Washington 1
Wenzhou 1
Zurich 1
Totale 290
Nome #
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 61
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 52
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 40
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 40
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 36
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 34
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 31
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 25
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 24
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 23
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 18
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 17
Infectious adverse events in patients with atopic dermatitis treated with baricitinib 9
Totale 410
Categoria #
all - tutte 3.088
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.088


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227 0 0 0 0 0 0 0 0 0 3 2 2
2022/2023161 3 21 12 21 11 14 8 20 28 13 9 1
2023/2024170 2 25 14 26 14 33 9 3 6 8 18 12
2024/202572 5 1 22 6 38 0 0 0 0 0 0 0
Totale 410